Palbociclib in combination with dexamethasone, bortezomib, and doxorubicin for pediatric relapsed acute lymphoblastic leukemia
Sushmitha Grama Srinivasan, Jennifer L Kamens, Lianna J Marks, Jay M S Balagtas, Jeffrey E Rubnitz, Tanja A Gruber · 2026
Read Palbociclib in combination with dexamethasone, bortezomib, and doxorubicin for pediatric relapsed acute lymphoblastic leukemia by Sushmitha Grama Srinivasan, Jennifer L Kamens, Lianna J Marks, Jay M S Balagtas, Jeffrey E Rubnitz, Tanja A Gruber (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13524859.txt.
Description
Sushmitha Grama Srinivasan and others describe, in a 2026 letter, the design and thinking behind a phase 1 study adding palbociclib to salvage chemotherapy for children with relapsed acute lymphoblastic leukemia. Results after relapse remain poor, and many children relapse even after cellular therapy. A drug blocking cell-cycle kinases CDK4 and CDK6 looked hopeful because the leukemia cells rarely lose the protein those kinases control.
Earlier lab work backed palbociclib alone and paired with bortezomib, and bortezomib itself had worked in relapsed disease. The trial therefore raises oral doses of the drug alongside dexamethasone, bortezomib, and doxorubicin, with approvals and guardian consent in place. The authors frame the regimen as a bridge plan, since cellular therapy works better at low disease burden and chemotherapy is needed while those cells are made.
Catalog record
| CREATOR | Sushmitha Grama Srinivasan, Jennifer L Kamens, Lianna J Marks, Jay M S Balagtas, Jeffrey E Rubnitz, Tanja A Gruber |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |